TP53 or Not TP53: That Is the Question

被引：0

作者：

Green, Steven D. ^{[1
]}

Zeidner, Joshua F. ^{[2
,3
]}

机构：

[1] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[3] Univ N Carolina, Dept Med, Div Hematol, 170 Manning Dr,Houpt Bldg,CB7305, Chapel Hill, NC 27599 USA

来源：

CLINICAL CANCER RESEARCH | 2022年 / 28卷 / 24期

关键词：

ACUTE MYELOID-LEUKEMIA; CLASSIFICATION; VALIDATION;

D O I：

10.1158/1078-0432.CCR-22-2664

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Azacitidine and venetoclax are a standard first-line regimen for patients with newly diagnosed unfit acute myeloid leukemia (AML). In a pooled subset analysis, TP53-mutated AML with poor-risk cytogenetics does not appear to benefit from the addition of venetoclax to azacitidine. This has clinical implications as these patients should be preferentially treated with alternative regimens.

引用

页码：5235 / 5237

页数：3

共 50 条

[21] Mutation and function of TP53
Milner, J
BRAIN PATHOLOGY, 2000, 10 (04) : 504 - 504
[22] TP53: an oncogene in disguise
T Soussi
K G Wiman
Cell Death & Differentiation, 2015, 22 : 1239 - 1249
[23] TP53 and liver carcinogenesis
Staib, F
Hussain, SP
Hofseth, LJ
Wang, XW
Harris, CC
HUMAN MUTATION, 2003, 21 (03) : 201 - 216
[24] Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
Beird, Hannah C.
Lin, Dimitri
Lazar, Alexander J.
Futreal, P. Andrew
JOURNAL OF PATHOLOGY, 2024, 263 (02): : 131 - 134
[25] Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
A Langerød
TI Andersen
I Bukholm
A-L Børresen Dale
Breast Cancer Research, 2 (Suppl 1)
[26] Prevalence of mutated TP53 on cDNA (but not on DNA template) in pleomorphic xanthoastrocytoma with positive TP53 immunohistochemistry
Zakrzewska, Magdalena
Szybka, Malgorzata
Biernat, Wojciech
Papierz, Tomasz
Rieske, Piotr
Liberski, Pawel P.
Zakrzewski, Krzysztof
CANCER GENETICS AND CYTOGENETICS, 2009, 193 (02) : 93 - 97
[27] A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA
Gemignani, F
Moreno, V
Landi, S
Moullan, N
Chabrier, A
Gutiérrez-Enríquez, S
Hall, J
Guino, E
Peinado, MA
Capella, G
Canzian, F
ONCOGENE, 2004, 23 (10) : 1954 - 1956
[28] INTRODUCING WILDTYPE TP53 IN TP53 MUTATED MYELOID LEUKEMIAS IMPROVES SENSITIVITY TO CHEMOTHERAPEUTIC DRUGS
Maity, Arnab
Illangeswaran, Raveen
Rajamani, Bharathi
Choudhury, Anurag
Velayudhan, Shaji
Kulkarni, Uday
Balasubramanian, Poonkuzhaki
EXPERIMENTAL HEMATOLOGY, 2024, 137
[29] A case of gastric cancer with heterogeneous components of EB virus (+)/TP53 (+) and EB virus (-)/TP53 (-)
Matsuda, Ikuo
Kan, Kazuomi
Doi, Sadayuki
Motoki, Yoshiyuki
Onodera, Masayuki
Hirota, Seiichi
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11766 - 11771
[30] TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status
Rigodanza, Luca
Andreossi, Gloria
Consagra, Angela
Sanna, Alessandro
Mattiuz, Giorgio
de Pourcq, Sven Jiulien Maria
Raddi, Marco Gabriele
Santini, Valeria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S403 - S403

← 1 2 3 4 5 →